Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Stomach Neoplasms 8Gastrointestinal Neoplasms 4Esophageal Neoplasms 3Biliary Tract Neoplasms 3Advanced Solid Tumors 3Neoplasms 2Colorectal Neoplasms 2Patients With Advanced or Metastatic Solid Tumors 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × S 1 (combination) × Clear all
NCT00400023 2024-09-03

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00479076 2011-01-26

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Sanofi

Phase 1 Completed
22 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡